Etavopivat History and Updates

40 events · 2020 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
40
Trial Milestones
0
Pivotal Publications
Etavopivat — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications20212022202320242025202620272028202920302031Trial: NCT07023029 2025-06-09 → 2025-09-12 (primary completion)Trial: NCT06612268 2025-02-17 → 2027-08-27 (primary completion)Trial: NCT06813924 2025-02-06 → 2025-05-27 (primary completion)Trial: NCT06609226 2025-01-10 → 2030-12-30 (primary completion)Trial: NCT06581627 2024-08-26 → 2024-10-31 (primary completion)Trial: NCT06433661 2024-05-28 → 2024-07-06 (primary completion)Trial: NCT06336018 2024-05-20 → 2025-08-01 (primary completion)Trial: NCT05725902 2024-03-09 → 2026-03-09 (primary completion)Trial: NCT05953584 2023-06-20 → 2027-09-20 (primary completion)Trial: NCT06198712 2023-01-12 → 2028-02-23 (primary completion)Trial: NCT05568225 2022-11-15 → 2024-07-15 (primary completion)Trial: NCT04987489 2022-03-28 → 2025-09-03 (primary completion)Trial: NCT04624659 2021-01-29 → 2026-02-06 (primary completion)Results posted — 2025-10-22 Trial results posted: NCT05568225 A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)today (2026-06-11)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-11Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Etavopivat since 2020, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (2)

Upcoming & expected milestones

Primary completion· ClinicalTrials.gov
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Primary completion· ClinicalTrials.gov
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Past events

2026
2025
Results posted· ClinicalTrials.gov
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Trial started· ClinicalTrials.gov
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
2024
Trial started· ClinicalTrials.gov
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
2023
Trial started· ClinicalTrials.gov
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell
Trial started· ClinicalTrials.gov
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
2022
Trial started· ClinicalTrials.gov
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
2021
2020

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.